ANZDATA Registry. 39th Report, Chapter 8: Transplantation. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, Australia. 2017. http://www.anzdata.org.au. Accessed 22 Nov 2017.
Madeleine MM, Patel NS, Plasmeijer EI, Engels EA, Bouwes Bavinck JN, Toland AE, et al. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol. 2017;177(5):1208–16.
Rüegg CP, Graf N, Mühleisen B, Szucs TD, French LE, Surber C, et al. Squamous cell carcinoma of the skin induces considerable sustained cost of care in organ transplant recipients. J Am Acad Dermatol. 2012;67(6):1242–9.
Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197(10):565–8.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Eng J Med. 2003;348(17):1681–91.
Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O’Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61(5):715–21.
Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49(3):506–9.
Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol. 2002;147(5):950–6.
Garrett GL, Blanc PD, Boscardin J. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296–303.
Harwood CA, Mesher D, McGregor JM, Mitchell L, Leedham-Green M, Raftery M, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant. 2013;13(1):119–29.
Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczeka H, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008: A Swedish population-based study. Int J Cancer. 2013;132(6):1429–38.
Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143(3):513–9.
Mackenzie KA, Wells JE, Lynn KL, Simcock JW, Robinson BA, Roake JA, et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transpl. 2010;25(1):300–6.
Moosa MR. Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine. 2005;84(1):12–22.
Ng JC, Cumming S, Leung V, Chong AH. Accrual of non-melanoma skin cancer in renal-transplant recipients: experience of a Victorian tertiary referral institution. Australas J Dermatol. 2014;55(1):43–8.
Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol. 1999;40:27–34.
Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among U.S. solid organ transplant recipients: the transplant cancer match study. JAMA. 2011;306(17):1891–901.
Arnold M, Holterhues C, Hollestein L, Coebergh J, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol. 2014;28(9):1170–8.
Guy G, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–7.
Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2):177–86.
Ingvar A, Smedby KE, Lindelöf B, Fernberg P, Bellocco R, Tufveson G, et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transpl. 2010;25(8):2764–71.
Harwood CA, Toland AE, Proby CM, Euvrard S, Hofbauer GFL, Tommasino M, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017;177(5):1217.
O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu Y-Z, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871–4.
Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med. 2015;4(6):1229–39.
Bouwes Bavinck JN, Feltkamp MCW, Green AC, Fiocco M, Euvrard S, Harwood CA, et al. Human papillomavirus and post-transplant cutaneous squamous-cell carcinoma: a multicenter, prospective cohort study. Am J Transpl [Internet]. 2017.
Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita M, Satoh T, et al. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.
Yu S, Gao F, Yu J, Yan S, Wu J, Zhang M, et al. De novo cancers following liver transplantation: a single center experience in China. PLoS One. 2014;9(1):e85651.
Park H, Hwang S, Ahn C, Kim K, Moon D, Ha T, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transpl Proc. 2012;44(3):802–5.
Proby CM, Wisgerhof HC, Casabonne D, Green AC, Harwood CA, Bouwes Bavinck JN. The epidemiology of transplant-associated keratinocyte cancers in different geographical regions. Cancer Treat Res. 2009;146:75–95.
Ducroux E, Martin C, Bouwes Bavinck JN, Decullier E, Brocard A, Westhuis-van Elsäcker ME, et al. Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: a retrospective study of 53 cases. Transplantation. 2017;101(4):e133–41.
Gogia R, Binstock M, Hirose R, Boscardin WJ, Chren M-M, Arron ST. Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation. J Am Acad Dermatol. 2013;68:585–91.
Rashtak S, Dierkhising R, Kremers W, Peters S, Cassivi S, Otley C. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015;72(1):92–8.
Martinez J, Otley C, Stasko T, Euvrard S, Brown C, Schanbacher C, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003;139(3):301–6.
Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. J Am Acad Dermatol. 2016;75(1):106–12.
Lindelöf B, Jarnvik J, Ternesten-Bratel A, Granath F, Hedblad M-A. Mortality and clinicopathological features of cutaneous squamous cell carcinoma in organ transplant recipients: a study of the Swedish cohort. Acta Derm Venereol. 2006;86(3):219–22.
Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl. 2001;7(11):971–5.
Iannacone MR, Sinnya S, Pandeya N, Isbel N, Campbell S, Fawcett J, et al. Prevalence of skin cancer and related skin tumors in high-risk kidney and liver transplant recipients in Queensland, Australia. J Invest Dermatol. 2016;136(7):1382–6.
Ducroux E, Boillot O, Ocampo MA, Decullier E, Roux A, Dumortier J, et al. Skin cancers after liver transplantation: retrospective single-center study on 371 recipients. Transplantation. 2014;98(3):335–40.
Krynitz B, Olsson H, Lundh Rozell B, Lindelof B, Edgren G, Smedby KE. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. Br J Dermatol. 2016;1:95.
Green A, Olsen C. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. Acta Derm Venereol. 2015;95(8):923–7.
Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer A-M, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104(9):1962–7.
Vajdic CM, Chong AH, Kelly PJ, Meagher NS, Van Leeuwen MT, Grulich AE, et al. Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study. Am J Transpl. 2014;14(6):1368–75.
Arron S, Canavan T, Yu S. Organ transplant recipients with Merkel cell carcinoma have reduced progression-free, overall, and disease-specific survival independent of stage at presentation. J Am Acad Dermatol. 2014;71(4):684–90.
Raeisi D, Payandeh M, Madani SH, Zare ME, Kansestani AN, Hashemian AH. Kaposi’s sarcoma after kidney transplantation: a 21-years experience. Int J Hematol Oncol Stem Cell Res. 2013;7(4):29–33.
Kang W, Sampaio MS, Huang E, Bunnapradist S. Association of pretransplant skin cancer with posttransplant malignancy, graft failure and death in kidney transplant recipients. Transplantation. 2017;101(6):1303–9.
Krynitz B, Rozell B, Lyth J, Smedby K, Lindelöf B. Cutaneous malignant melanoma in the Swedish organ transplantation cohort: a study of clinicopathological characteristics and mortality. J Am Acad Dermatol. 2015;73(1):106–13.e2.
Teulings H-E, Limpens J, Jansen S, Zwinderman A, Reitsma J, Spuls P, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–81.
Kanitakis J, Baldassini S, Lora V, Euvrard S. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol. 2010;20(2):167–71.
Lee J, Choi J, Kim Y. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776–84.
Brocard A, Knol A, Bossard C, Denis M, Quéreux G, Saint-Jean M, et al. Clinical, genetic and innate immunity characteristics of melanoma in organ transplant recipients. Acta Derm Venereol. 2017;97(4):483–8.
Clarke C, Robbins H, Tatalovich Z, Lynch C, Pawlish K, Finch J, et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst. 2015;107(2):dju382.
Sharp C, Norja P, Anthony I, Bell J, Simmonds P. Reactivation and mutation of newly discovered WU, KI, and Merkel cell carcinoma polyomaviruses in immunosuppressed individuals. J Infect Dis. 2009;199(3):398–404.
Antman K, Chang Y. Kaposi’s sarcoma. N Eng J Med. 2000;342(14):1027–38.
Harwood CA, McGregor JM, Swale VJ, Proby CM, Leigh IM, Newton R, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. 2003;48(3):401–8.
Wheless L, Jacks S, Potter KAM, Leach BC, Cook J. Skin cancer in organ transplant recipients: more than the immune system. J Am Acad Dermatol. 2014;71(2):359–65.
Kaufmann R, Oberholzer P, Cazzaniga S, Hunger R. Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. Eur J Dermatol. 2016;26(3):265–70.
Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease dna repair and apoptosis in human keratinocytes following ultraviolet b irradiation. J Invest Dermatol. 2005;125:1020–5.
Dziunycz P, Lefort K, Wu X, Freiberger S, Neu J, Djerbi N, et al. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A. J Invest Dermatol. 2014;134(7):1998–2004.
Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.
Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Fauchald P. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transpl Proc. 1999;31(1–2):1120.
Crespo-Leiro M, Alonso-Pulpón L, Vázquez de Prada J, Almenar L, Arizón J, Brossa V, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transpl. 2008;8(5):1031–9.
Molina B, Leiro M, Pulpón L, Mirabet S, Yañez J, Bonet L, et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transpl Proc. 2010;42(8):3001–5.
Ming M, Zhao B, Qiang L, He Y-Y. Effect of Immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol. 2015;1:242.
Wu X, Nguyen B, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature. 2010;465(7296):368–72.
Kasiske B, Snyder J, Gilbertson D, Wang C. Cancer after kidney transplantation in the United States. Am J Transpl. 2004;4(6):905–13.
Navarro M, López-Andréu M, Rodríguez-Benot A, Agüera M, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transpl Proc. 2008;40(9):2936–40.
Krásová M, Sečníková Z, Göpfertová D, Hercogová J, Viklický O, Jůzlová K, et al. Immunosuppressive therapy in the posttransplant period and skin cancer. Dermatol Ther. 2016;29(6):433–6.
Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transpl. 2011;16(2):14–8.
Wimmer C, Angele M, Schwarz B, Pratschke S, Rentsch M, Khandoga A, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int. 2013;26(10):999–1006.
Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ (Clinical Research Ed). 2014;349:g6679–g.
Jung J-W, Overgaard NH, Burke MT, Isbel N, Frazer IH, Simpson F, et al. Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? Int J Cancer. 2016;138(2):281–92.
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883–9.
Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004;18(4):446–9.
Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Eng J Med. 2012;367(4):329–39.
Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013;31(10):1317–23.
Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transpl. 2014;14(9):2106–19.
de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101(1):45–55.
Feldmeyer L, Hofbauer GFL, Böni T, French LE, Hafner J. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. Br J Dermatol. 2012;166(2):422–4.
Meier F, Guenova E, Clasen S, Eigentler T, Forschner A, Leiter U, et al. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol. 2009;60(5):863–8.
Guven M, Brem R, Macpherson P, Peacock M, Karran P. Oxidative damage to RPA limits the nucleotide excision repair capacity of human cells. J Invest Dermatol. 2015;135(11):2834–41.
Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transpl. 2016;16(12):3490–503.
Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madele MM. Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort. Am J Transpl. 2016;16(2):565–73.
de Gruijl FR, Koehl GE, Voskamp P, Strik A, Rebel HG, Gaumann A, et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer. 2010;127(4):796–804.
Aguiar D, Martínez-Urbistondo D, D’Avola D, Iñarrairaegui M, Pardo F, Rotellar F, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation. Ann Transpl. 2017;22:141–7.
Piponniau L, Kittleson M, Patel J, Rafiei M, Osborne A, Dhiantravan V, et al. Mycophenolate not azathioprine is associated with increased risk for skin cancer after heart transplant. J Heart Lung Transpl. 2013;32(4):S199.
Wang YJ, Chi NH, Chou NK, Huang SC, Wang CH, Wu IH, et al. Malignancy after heart transplantation under everolimus versus mycophenolate mofetil immunosuppression. Transpl Proc. 2016;48(3):969–73.
Dharnidharka V, Schnitzler M, Chen J, Brennan D, Axelrod D, Segev D, et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int. 2016;29(11):1226–36.
Gerber SR, Seifert B, Inci I, Serra AL, Kohler M, Benden C, et al. Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. J Eur Acad Dermatol Venereol. 2015;12:2451.
Browne BJ, Young J-A, Dunn TB, Matas AJ. The impact of cytomegalovirus infection ≥ 1 year after primary renal transplantation. Clin Transplant. 2010;24(4):572–7.
Hasanzamani B, Hami M, Zolfaghari V, Torkamani M, Sabagh MG, Simab SA. The effect of cytomegalovirus infection on acute rejection in kidney transplanted patients. J Renal Inj Prev. 2016;5(2):85–8.
Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol. 1997;37(3 Pt 1):365–81.
Neoh CF, Snell GI, Levvey B, Kotsimbos T, Morrissey O, Slavin MA, et al. Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. Med J Aust. 2014;201(9):543–4.
Mansh M, Binstock M, Williams K, Hafeez F, Kim J, Glidden D, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma, aspergillus colonization, invasive aspergillosis and death in lung transplant recipients. Am J Transpl. 2016;16(1):262–70.
Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997–1002.
Kolaitis NA, Duffy E, Zhang A, Lo M, Barba DT, Chen M, et al. Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation. Transpl Int. 2017;30(1):41–8.
Jacobsen AA, Papo YB, Sarro R, Weisse K, Strasswimmer J. Posaconazole substitution for voriconazole-associated phototoxic effects. JAMA Dermatol. 2016;152(7):839–41.
Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg. 2000;26(7):709–12.
Patel P, Bibee K, Lim G, Malik S, Wu C, Pugliano-Mauro M. Evaluating retention of skin cancer education in kidney transplant recipients reveals a window of opportunity for re-education. Transpl Proc. 2017;49(6):1318–24.
Lloyd A, Klintmalm G, Qin H, Menter A. Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations. Clin Transpl. 2015;29(2):110–7.
Christenson L, Geusau A, Ferrandiz C, Brown C, Ulrich C, Stockfleth E, et al. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatol Surg. 2004;30(4):598–603.
Clowers-Webb HE, Christenson LJ, Phillips PK, Roenigk RK, Nguyen TH, Weaver AL, et al. Educational outcomes regarding skin cancer in organ transplant recipients: randomized intervention of intensive vs standard education. Arch Dermatol. 2006;142(6):712–8.
Leung VKY, Dobbinson SJ, Goodman DJ, Kanellis J, Chong AH. Skin cancer history, sun-related attitudes, behaviour and sunburn among renal transplant recipients versus general population. Australas J Dermatol. 2017.
Ulrich C, Jürgensen J, Degen A, Hackethal M, Ulrich M, Patel M, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(S3):78–84.
Reichrath J. Solar ultraviolet radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs): an update. Adv Exp Med Biol. 2014;810:253–71.
Ismail F, Mitchell L, Casabonne D, Gulati A, Newton R, Proby CM, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol. 2006;155(5):916–25.
O’Reilly Zwald F, Brown M. Continuing medical education: skin cancer in solid organ transplant recipients: Advances in therapy and management. Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263–79.
Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933–8.
George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43(4):269–73.
Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol. 2005;141(4):456–64.
De Graaf YGL, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):656–61.
Chen AC, Martin AJ, Choy B, Fernandez-Penas P, McKenzie CA, Vardy JL, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Eng J Med. 2015;373(17):1618–26.
Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016;175(5):1073–5.
Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano L, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case–control study. Eur J Dermatol. 2017;27(4):382–5.
Otley C, Berg D, Ulrich C, Stasko T, Murphy G, Salasche S, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154(3):395–400.
Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623–8.